Literature DB >> 27479816

Chronic lymphocytic leukemia development is accelerated in mice with deficiency of the pro-apoptotic regulator NOXA.

Erik Slinger1, Felix M Wensveen2, Jeroen E Guikema3, Arnon P Kater4, Eric Eldering5.   

Abstract

Entities:  

Keywords:  NOXA; chronic lymphocytic leukemia; oncomodulator

Mesh：

Substances：

Year:  2016        PMID： 27479816      PMCID： PMC5060034          DOI： 10.3324/haematol.2016.142323

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  BH3-only protein Noxa regulates apoptosis in activated B cells and controls high-affinity antibody formation.

Authors:  Felix M Wensveen; Ingrid A M Derks; Klaas P J M van Gisbergen; Alex M de Bruin; Joost C M Meijers; HaciAli Yigittop; Martijn A Nolte; Eric Eldering; René A W van Lier
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

2.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.

Authors:  Lin Chen; Simon N Willis; Andrew Wei; Brian J Smith; Jamie I Fletcher; Mark G Hinds; Peter M Colman; Catherine L Day; Jerry M Adams; David C S Huang
Journal:  Mol Cell       Date:  2005-02-04       Impact factor: 17.970

3.  Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity.

Authors:  Laura A Smit; Delfine Y H Hallaert; René Spijker; Bart de Goeij; Annelieke Jaspers; Arnon P Kater; Marinus H J van Oers; Carel J M van Noesel; Eric Eldering
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

4.  Apoptosis threshold set by Noxa and Mcl-1 after T cell activation regulates competitive selection of high-affinity clones.

Authors:  Felix M Wensveen; Klaas P J M van Gisbergen; Ingrid A M Derks; Carmen Gerlach; Ton N Schumacher; René A W van Lier; Eric Eldering
Journal:  Immunity       Date:  2010-06-25       Impact factor: 31.745

5.  Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.

Authors:  Jacqueline M Tromp; Christian R Geest; Esther C W Breij; Judith A Elias; Jacoline van Laar; Dieuwertje M Luijks; Arnon P Kater; Tim Beaumont; Marinus H J van Oers; Eric Eldering
Journal:  Clin Cancer Res       Date:  2011-11-29       Impact factor: 12.531

6.  Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation.

Authors:  W J M Mackus; A P Kater; A Grummels; L M Evers; B Hooijbrink; M H H Kramer; J E Castro; T J Kipps; R A W van Lier; M H J van Oers; E Eldering
Journal:  Leukemia       Date:  2005-03       Impact factor: 11.528

7.  Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.

Authors:  Roberta Bichi; Susan A Shinton; Eric S Martin; Anatoliy Koval; George A Calin; Rossano Cesari; Giandomenico Russo; Richard R Hardy; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

Review 8.  Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.

Authors:  Elisa Ten Hacken; Jan A Burger
Journal:  Biochim Biophys Acta       Date:  2015-07-17

Review 9.  The BCL-2 protein family, BH3-mimetics and cancer therapy.

Authors:  A R D Delbridge; A Strasser
Journal:  Cell Death Differ       Date:  2015-05-08       Impact factor: 15.828

10.  Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).

Authors:  J D Leverson; H Zhang; J Chen; S K Tahir; D C Phillips; J Xue; P Nimmer; S Jin; M Smith; Y Xiao; P Kovar; A Tanaka; M Bruncko; G S Sheppard; L Wang; S Gierke; L Kategaya; D J Anderson; C Wong; J Eastham-Anderson; M J C Ludlam; D Sampath; W J Fairbrother; I Wertz; S H Rosenberg; C Tse; S W Elmore; A J Souers
Journal:  Cell Death Dis       Date:  2015-01-15       Impact factor: 8.469
View more
  4 in total

1.  Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci.

Authors:  Huihuang Yan; Shulan Tian; Geffen Kleinstern; Zhiquan Wang; Jeong-Heon Lee; Nicholas J Boddicker; James R Cerhan; Neil E Kay; Esteban Braggio; Susan L Slager
Journal:  Hum Mol Genet       Date:  2020-09-29       Impact factor: 6.150

2.  Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells.

Authors:  Parviz Kokhaei; Mohammad Hojjat-Farsangi; Fariba Mozaffari; Ali Moshfegh; Fatemeh Pak; Ali Rashidy-Pour; Marzia Palma; Lotta Hansson; Anders Österborg; Håkan Mellstedt
Journal:  PLoS One       Date:  2018-02-12       Impact factor: 3.240

3.  The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax.

Authors:  Ana M Cosialls; Helena Pomares; Daniel Iglesias-Serret; José Saura-Esteller; Sonia Núñez-Vázquez; Diana M González-Gironès; Esmeralda de la Banda; Sara Preciado; Fernando Albericio; Rodolfo Lavilla; Gabriel Pons; Eva M González-Barca; Joan Gil
Journal:  Haematologica       Date:  2017-06-15       Impact factor: 9.941

4.  Drug efficacy and toxicity prediction: an innovative application of transcriptomic data.

Authors:  Xuhua Xia
Journal:  Cell Biol Toxicol       Date:  2020-08-11       Impact factor: 6.691
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.